Meadow Creek Investment Management LLC Raises Stake in Becton Dickinson and Co (BDX)

Meadow Creek Investment Management LLC boosted its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 6.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 31,246 shares of the medical instruments supplier’s stock after purchasing an additional 1,904 shares during the period. Meadow Creek Investment Management LLC’s holdings in Becton Dickinson and were worth $6,688,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the business. BlackRock Inc. lifted its stake in Becton Dickinson and by 6.0% during the 4th quarter. BlackRock Inc. now owns 18,811,302 shares of the medical instruments supplier’s stock valued at $4,026,750,000 after acquiring an additional 1,071,288 shares during the period. Franklin Resources Inc. lifted its stake in Becton Dickinson and by 1.6% during the 4th quarter. Franklin Resources Inc. now owns 3,689,932 shares of the medical instruments supplier’s stock valued at $789,867,000 after acquiring an additional 57,002 shares during the period. Geode Capital Management LLC lifted its stake in Becton Dickinson and by 3.4% during the 4th quarter. Geode Capital Management LLC now owns 2,216,435 shares of the medical instruments supplier’s stock valued at $473,373,000 after acquiring an additional 72,358 shares during the period. Renaissance Technologies LLC lifted its stake in Becton Dickinson and by 1,192.1% during the 4th quarter. Renaissance Technologies LLC now owns 2,074,503 shares of the medical instruments supplier’s stock valued at $444,068,000 after acquiring an additional 1,913,952 shares during the period. Finally, Bank of New York Mellon Corp lifted its stake in Becton Dickinson and by 1.4% during the 4th quarter. Bank of New York Mellon Corp now owns 2,010,236 shares of the medical instruments supplier’s stock valued at $430,312,000 after acquiring an additional 26,956 shares during the period. 83.40% of the stock is currently owned by institutional investors.

In related news, Director Timothy M. Ring sold 269,661 shares of the company’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $217.82, for a total value of $58,737,559.02. Following the completion of the sale, the director now owns 295,753 shares of the company’s stock, valued at $64,420,918.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Thomas E. Polen, Jr. sold 1,877 shares of the company’s stock in a transaction dated Tuesday, March 13th. The shares were sold at an average price of $227.00, for a total transaction of $426,079.00. Following the completion of the sale, the executive vice president now directly owns 15,387 shares of the company’s stock, valued at approximately $3,492,849. The disclosure for this sale can be found here. Insiders have sold 281,108 shares of company stock valued at $61,321,396 in the last ninety days. Insiders own 1.00% of the company’s stock.

Shares of NYSE BDX opened at $215.50 on Friday. The firm has a market capitalization of $58,248.53, a P/E ratio of 22.73, a P/E/G ratio of 1.59 and a beta of 1.15. The company has a quick ratio of 0.93, a current ratio of 1.54 and a debt-to-equity ratio of 1.04. Becton Dickinson and Co has a one year low of $175.66 and a one year high of $248.39.

Becton Dickinson and (NYSE:BDX) last released its earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.41 by $0.07. Becton Dickinson and had a net margin of 2.71% and a return on equity of 16.19%. The business had revenue of $3.08 billion during the quarter, compared to analyst estimates of $3.05 billion. During the same quarter in the prior year, the firm earned $2.33 earnings per share. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. equities research analysts expect that Becton Dickinson and Co will post 10.95 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Friday, March 30th. Stockholders of record on Friday, March 9th were issued a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.39%. The ex-dividend date of this dividend was Thursday, March 8th. Becton Dickinson and’s payout ratio is 31.65%.

Several analysts have commented on BDX shares. Argus lifted their price objective on shares of Becton Dickinson and to $235.00 and gave the company a “buy” rating in a research note on Thursday, December 14th. They noted that the move was a valuation call. KeyCorp started coverage on shares of Becton Dickinson and in a research note on Friday, January 5th. They issued an “overweight” rating and a $260.00 target price for the company. Bank of America reiterated a “buy” rating and issued a $260.00 target price on shares of Becton Dickinson and in a research note on Friday, January 19th. Deutsche Bank set a $260.00 target price on shares of Becton Dickinson and and gave the company a “buy” rating in a research note on Friday, December 29th. Finally, Evercore ISI started coverage on shares of Becton Dickinson and in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $245.00 target price for the company. Six research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $240.53.

WARNING: This news story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/04/07/meadow-creek-investment-management-llc-has-6-69-million-position-in-becton-dickinson-and-co-bdx.html.

Becton Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply